CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells

Authors

Keywords

Journal

Volume 23, Issue 7, Pages 1329-1336

Publisher

Springer Nature

Online

2009-04-16

DOI

10.1038/leu.2009.77

Explore over 38,000 international journals covering a vast array of academic fields.

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now